# Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer

- Source: PR Newswire M&A
- Published: 2026-11-08T16:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/johnson--johnson-reports-73-psa-response-rate-with-investigational-pasritamig-based-immunotherapy-combination-in-advanced-prostate-cancer-302932750.html
- Canonical: https://groundlevelnews.com/story/johnson-johnson-reports-73-psa-response-rate-with-investigational-pasr-470cf4/

First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activate T cells against cancer Deep and sustained PSA responses observed with every-six-week dosing, with 73% (11...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._